What is XYNTHA?

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for the prevention of bleeding during surgery in patients with hemophilia A.

XYNTHA does not contain von Willebrand factor and, therefore, is not indicated for von Willebrand's disease.

You are leaving XYNTHA.com

You are leaving this website. Links to all outside websites are provided as a convenience to our visitors and do not imply an endorsement or recommendation by Pfizer. Pfizer accepts no responsibility or liability for the content or services of other websites.

What Is XYNTHA?

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for the prevention of bleeding during surgery in patients with hemophilia A.

XYNTHA does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand's disease.

Important Safety Information for XYNTHA

Call your healthcare provider or go to the emergency department right away if you have any of the following symptoms because these may be signs of a serious allergic reaction: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, low blood pressure, or hives. XYNTHA contains trace amounts of hamster protein. You may develop an allergic reaction to these proteins. Tell your healthcare provider if you have had an allergic reaction to hamster protein

Call your healthcare provider right away if bleeding is not controlled after using XYNTHA; this may be a sign of an inhibitor, an antibody that may stop XYNTHA from working properly. Your healthcare provider may need to take blood tests to monitor for inhibitors

Across all clinical studies, the most common side effects (10% or more) with XYNTHA in adult and pediatric previously treated patients (PTPs) were headache (26% of subjects), joint pain (25%), fever (21%), and cough (11%). Other side effects reported in 5% or more of patients were: diarrhea, vomiting, weakness, and nausea

XYNTHA is an injectable medicine administered by intravenous (IV) infusion. You may experience local irritation when infusing XYNTHA after reconstitution in XYNTHA® SOLOFUSE®.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions about patient care must be made with a health care provider, considering the unique characteristics of the patient.

The product information provided in this site is intended for residents of the United States. The products discussed herein may have different product labeling in different countries.

PP-XYN-USA-0118-01

Important Safety Information

What Is XYNTHA?

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for the prevention of bleeding during surgery in patients with hemophilia A.

XYNTHA does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand's disease.

Important Safety Information for XYNTHA

Call your healthcare provider or go to the emergency department right away if you have any of the following symptoms because these may be signs of a serious allergic reaction: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, low blood pressure, or hives. XYNTHA contains trace amounts of hamster protein. You may develop an allergic reaction to these proteins. Tell your healthcare provider if you have had an allergic reaction to hamster protein

Call your healthcare provider right away if bleeding is not controlled after using XYNTHA; this may be a sign of an inhibitor, an antibody that may stop XYNTHA from working properly. Your healthcare provider may need to take blood tests to monitor for inhibitors

Across all clinical studies, the most common side effects (10% or more) with XYNTHA in adult and pediatric previously treated patients (PTPs) were headache (26% of subjects), joint pain (25%), fever (21%), and cough (11%). Other side effects reported in 5% or more of patients were: diarrhea, vomiting, weakness and nausea

XYNTHA is an injectable medicine administered by intravenous (IV) infusion. You may experience local irritation when infusing XYNTHA after reconstitution in XYNTHA® SOLOFUSE®.